Search

Your search keyword '"Kaymakoglu S"' showing total 7 results
Start Over Author "Kaymakoglu S" Publisher wiley
7 results on '"Kaymakoglu S"'

1. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Author

Razavi, H., primary, Waked, I., additional, Sarrazin, C., additional, Myers, R. P., additional, Idilman, R., additional, Calinas, F., additional, Vogel, W., additional, Mendes Correa, M. C., additional, Hézode, C., additional, Lázaro, P., additional, Akarca, U., additional, Aleman, S., additional, Balık, İ., additional, Berg, T., additional, Bihl, F., additional, Bilodeau, M., additional, Blasco, A. J., additional, Brandão Mello, C. E., additional, Bruggmann, P., additional, Buti, M., additional, Calleja, J. L., additional, Cheinquer, H., additional, Christensen, P. B., additional, Clausen, M., additional, Coelho, H. S. M., additional, Cramp, M. E., additional, Dore, G. J., additional, Doss, W., additional, Duberg, A. S., additional, El-Sayed, M. H., additional, Ergör, G., additional, Esmat, G., additional, Falconer, K., additional, Félix, J., additional, Ferraz, M. L. G., additional, Ferreira, P. R., additional, Frankova, S., additional, García-Samaniego, J., additional, Gerstoft, J., additional, Giria, J. A., additional, Gonçales, F. L., additional, Gower, E., additional, Gschwantler, M., additional, Guimarães Pessôa, M., additional, Hindman, S. J., additional, Hofer, H., additional, Husa, P., additional, Kåberg, M., additional, Kaita, K. D. E., additional, Kautz, A., additional, Kaymakoglu, S., additional, Krajden, M., additional, Krarup, H., additional, Laleman, W., additional, Lavanchy, D., additional, Marinho, R. T., additional, Marotta, P., additional, Mauss, S., additional, Moreno, C., additional, Murphy, K., additional, Negro, F., additional, Nemecek, V., additional, Örmeci, N., additional, Øvrehus, A. L. H., additional, Parkes, J., additional, Pasini, K., additional, Peltekian, K. M., additional, Ramji, A., additional, Reis, N., additional, Roberts, S. K., additional, Rosenberg, W. M., additional, Roudot-Thoraval, F., additional, Ryder, S. D., additional, Sarmento-Castro, R., additional, Semela, D., additional, Sherman, M., additional, Shiha, G. E., additional, Sievert, W., additional, Sperl, J., additional, Stärkel, P., additional, Stauber, R. E., additional, Thompson, A. J., additional, Urbanek, P., additional, Van Damme, P., additional, van Thiel, I., additional, Van Vlierberghe, H., additional, Vandijck, D., additional, Wedemeyer, H., additional, Weis, N., additional, Wiegand, J., additional, Yosry, A., additional, Zekry, A., additional, Cornberg, M., additional, Müllhaupt, B., additional, and Estes, C., additional

Published
2014
Full Text
View/download PDF

2. Historical epidemiology of hepatitis C virus (HCV) in selected countries

Author

Bruggmann, P., primary, Berg, T., additional, Øvrehus, A. L. H., additional, Moreno, C., additional, Brandão Mello, C. E., additional, Roudot‐Thoraval, F., additional, Marinho, R. T., additional, Sherman, M., additional, Ryder, S. D., additional, Sperl, J., additional, Akarca, U., additional, Balık, İ., additional, Bihl, F., additional, Bilodeau, M., additional, Blasco, A. J., additional, Buti, M., additional, Calinas, F., additional, Calleja, J. L., additional, Cheinquer, H., additional, Christensen, P. B., additional, Clausen, M., additional, Coelho, H. S. M., additional, Cornberg, M., additional, Cramp, M. E., additional, Dore, G. J., additional, Doss, W., additional, Duberg, A. S., additional, El‐Sayed, M. H., additional, Ergör, G., additional, Esmat, G., additional, Estes, C., additional, Falconer, K., additional, Félix, J., additional, Ferraz, M. L. G., additional, Ferreira, P. R., additional, Frankova, S., additional, García‐Samaniego, J., additional, Gerstoft, J., additional, Giria, J. A., additional, Gonçales, F. L., additional, Gower, E., additional, Gschwantler, M., additional, Guimarães Pessôa, M., additional, Hézode, C., additional, Hofer, H., additional, Husa, P., additional, Idilman, R., additional, Kåberg, M., additional, Kaita, K. D. E., additional, Kautz, A., additional, Kaymakoglu, S., additional, Krajden, M., additional, Krarup, H., additional, Laleman, W., additional, Lavanchy, D., additional, Lázaro, P., additional, Marotta, P., additional, Mauss, S., additional, Mendes Correa, M. C., additional, Müllhaupt, B., additional, Myers, R. P., additional, Negro, F., additional, Nemecek, V., additional, Örmeci, N., additional, Parkes, J., additional, Peltekian, K. M., additional, Ramji, A., additional, Razavi, H., additional, Reis, N., additional, Roberts, S. K., additional, Rosenberg, W. M., additional, Sarmento‐Castro, R., additional, Sarrazin, C., additional, Semela, D., additional, Shiha, G. E., additional, Sievert, W., additional, Stärkel, P., additional, Stauber, R. E., additional, Thompson, A. J., additional, Urbanek, P., additional, van Thiel, I., additional, Van Vlierberghe, H., additional, Vandijck, D., additional, Vogel, W., additional, Waked, I., additional, Wedemeyer, H., additional, Weis, N., additional, Wiegand, J., additional, Yosry, A., additional, Zekry, A., additional, Van Damme, P., additional, Aleman, S., additional, and Hindman, S. J., additional

Published
2014
Full Text
View/download PDF

3. Strategies to manage hepatitis C virus (HCV) disease burden

Author

Wedemeyer, H., primary, Duberg, A. S., additional, Buti, M., additional, Rosenberg, W. M., additional, Frankova, S., additional, Esmat, G., additional, Örmeci, N., additional, Van Vlierberghe, H., additional, Gschwantler, M., additional, Akarca, U., additional, Aleman, S., additional, Balık, İ., additional, Berg, T., additional, Bihl, F., additional, Bilodeau, M., additional, Blasco, A. J., additional, Brandão Mello, C. E., additional, Bruggmann, P., additional, Calinas, F., additional, Calleja, J. L., additional, Cheinquer, H., additional, Christensen, P. B., additional, Clausen, M., additional, Coelho, H. S. M., additional, Cornberg, M., additional, Cramp, M. E., additional, Dore, G. J., additional, Doss, W., additional, El-Sayed, M. H., additional, Ergör, G., additional, Estes, C., additional, Falconer, K., additional, Félix, J., additional, Ferraz, M. L. G., additional, Ferreira, P. R., additional, García-Samaniego, J., additional, Gerstoft, J., additional, Giria, J. A., additional, Gonçales, F. L., additional, Guimarães Pessôa, M., additional, Hézode, C., additional, Hindman, S. J., additional, Hofer, H., additional, Husa, P., additional, Idilman, R., additional, Kåberg, M., additional, Kaita, K. D. E., additional, Kautz, A., additional, Kaymakoglu, S., additional, Krajden, M., additional, Krarup, H., additional, Laleman, W., additional, Lavanchy, D., additional, Lázaro, P., additional, Marinho, R. T., additional, Marotta, P., additional, Mauss, S., additional, Mendes Correa, M. C., additional, Moreno, C., additional, Müllhaupt, B., additional, Myers, R. P., additional, Nemecek, V., additional, Øvrehus, A. L. H., additional, Parkes, J., additional, Peltekian, K. M., additional, Ramji, A., additional, Razavi, H., additional, Reis, N., additional, Roberts, S. K., additional, Roudot-Thoraval, F., additional, Ryder, S. D., additional, Sarmento-Castro, R., additional, Sarrazin, C., additional, Semela, D., additional, Sherman, M., additional, Shiha, G. E., additional, Sperl, J., additional, Stärkel, P., additional, Stauber, R. E., additional, Thompson, A. J., additional, Urbanek, P., additional, Van Damme, P., additional, van Thiel, I., additional, Vandijck, D., additional, Vogel, W., additional, Waked, I., additional, Weis, N., additional, Wiegand, J., additional, Yosry, A., additional, Zekry, A., additional, Negro, F., additional, Sievert, W., additional, and Gower, E., additional

Published
2014
Full Text
View/download PDF

5. A short course of add‐on adefovir dipivoxil treatment in lamivudine‐resistant chronic hepatitis B patients

Author

Idilman, R., primary, Kaymakoglu, S., additional, Oguz Onder, F., additional, Ahishali, E., additional, Bektas, M., additional, Cinar, K., additional, Pınarbasi, B., additional, Karayalcin, S., additional, Badur, S., additional, Cakaloglu, Y., additional, Mithat Bozdayi, A., additional, Bozkaya, H., additional, Ökten, A., additional, and Yurdaydin, C., additional

Published
2009
Full Text
View/download PDF

7. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real‐world chronic hepatitis C patients cohort

Author

Alkim, Huseyin, Kaymakoglu, Sabahattin, TABAK, Ömer Fehmi, GÜNŞAR, FULYA, AKHAN, SILA, İDİLMAN, RAMAZAN, DEMİR, MEHMET, ALADAĞ, MURAT, Erol, Cihan, Cavus, Bilger, Iliaz, Raim, Koklu, Hayrettin, Cakaloglu, Yilmaz, Sahin, Memduh, ERSÖZ, GALİP, Koksal, Iftihar, KARASU, ABDULLAH ZEKİ, Ozgenel, Meric, TURAN, İLKER, GÜNDÜZ, FEYZA, ATASEVEN , HÜSEYİN, Akdogan, Meral, KIYICI, MURAT, Ozkan, Hasan, Ozer, Birol, AKARSU, MESUT, Kuruuzum, Ziya, Yurdaydin, Cihan, Yozgat, Ahmet, Yilmaz, Hasan, Yilmaz, Bulent, Yildirim, Beytullah, Yildirim, Abdullah E., KÖKSAL, AYDIN ŞEREF, Yaras, Serkan, Unal, Hakan, Toka, Bilal, Simsek, Halis, Senates, Ebubekir, Poturoglu, Sule, Ozenirler, Seren, Ozbakir, Omer, Ormeci, Necati, ÖNDER, Fatih Oğuz, Kav, Taylan, Kamilli, Cemil, Inkaya, Ahmet Cagan, Gursoy, Sebnem, Gurel, Selim, Gokcan, Hale, Ensaroglu, Fatih, Cosgun, Suleyman, Celik, Ilhami, Bolat, Aylin, Baysal, Birol, Barut, Huseyin S., Balik, Ismail, Aygen, Bilgehan, Ates, Fehmi, Araz, Filiz, Akarca, Ulus S., Idilman, R, Demir, M, Aladag, M, Erol, C, Cavus, B, Iliaz, R, Koklu, H, Cakaloglu, Y, Sahin, M, Ersoz, G, Koksal, I, Karasu, Z, Ozgenel, M, Turan, I, Gunduz, F, Ataseven, H, Akdogan, M, Kiyici, M, Koksal, AS, Akhan, S, Gunsar, F, Tabak, F, Kaymakoglu, S, Akarca, US, Akarsu, M, Alkim, H, Araz, F, Ates, F, Aygen, B, Balik, I, Barut, HS, Baysal, B, Bolat, A, Celik, I, Cosgun, S, Ensaroglu, F, Gokcan, H, Gurel, S, Gursoy, S, Inkaya, AC, Kamilli, C, Kav, T, Kuruuzum, Z, Onder, FO, Ormeci, N, Ozbakir, O, Ozenirler, S, Ozer, B, Ozkan, H, Poturoglu, S, Senates, E, Simsek, H, Toka, B, Unal, H, Yaras, S, Yildirim, AE, Yildirim, B, Yilmaz, B, Yilmaz, H, Yozgat, A, Yurdaydin, C, Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Köksal, Aydın Şeref, and Toka, Bilal

Subjects
Male, Cirrhosis, Sustained Virologic Response, Sofosbuvir, viruses, medicine.medical_treatment, Hepacivirus, Liver transplantation, Gastroenterology, Cohort Studies, chemistry.chemical_compound, Liver disease, 0302 clinical medicine, 030212 general & internal medicine, Aged, 80 and over, Liver Neoplasms, Middle Aged, Infectious Diseases, Hepatocellular carcinoma, RNA, Viral, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Uridine Monophosphate, medicine.drug, Adult, Ledipasvir, medicine.medical_specialty, Carcinoma, Hepatocellular, Genotype, Antiviral Agents, 03 medical and health sciences, Virology, Internal medicine, Ribavirin, medicine, Humans, Aged, Fluorenes, Hepatology, business.industry, Hepatitis C, Chronic, medicine.disease, digestive system diseases, Liver Transplantation, chemistry, Benzimidazoles, Liver function, Neoplasm Recurrence, Local, business
Abstract

The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22 months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P < 0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6 months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P = 0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results